ABT Abbott Laboratories · Healthcare
1 research call since Oct 14. Latest view: Lean bullish
Last close
$102.64 2026-10-28
Latest call vs SPY
+0.8% since 2026-10-13
Technical scan
Strong Buy rank 64 of 127
Price, last 12 months daily close · markers are published calls
Current technical signals nightly scan, 2026-10-28
MACD: Bullish WeakeningOBV: Confirmed Uptrend
Notable moves days ABT was among the market's biggest movers
- 2026-09-11 -1.4% Top decliner of the day · $101.95
What would change the latest view
- Q3 adj EPS below $1.38 (bottom of guide) or FY26 guidance cut — breaks the delivery thesis
- CGM comparable growth decelerating below ~7% or new Libre safety actions
- FY27 consensus EPS revised below ~$5.90 — signals Exact accretion path slipping
- Stock fails to hold ~$95 (post-Q2 base) after earnings — market rejecting the repair narrative
All calls on ABT
ABT
Lean bullish
Oct 14, 2026
· Abbott Laboratories
· edge 5.5/10· evidence 7/10
Fundamentals support it — mildly.
ABT de-rated ~37% peak-to-trough on three identifiable shocks — $20B-debt-funded Exact Sciences acquisition (~$0.20 FY26 EPS dilution), a Class I Libre 3 recall, and weak respiratory-testing comps — none of which impaired the core franchise. Q2 2026 confirmed stabilization: adj EPS beat, FY26 adj EPS guidance raised to $5.45-5.60, CGM comparable growth accelerated from 7.6% to…
Entry $102.61 (2026-10-13)
1m vs SPY: +0.8% so far
Want a fresh deep analysis on ABT?
We analyze it in depth and publish here, usually within about 5 minutes; leave an email and we tell you when it is ready.